Abstract
Total mesorectal excision (TME) for rectal cancer is now considered standard in the surgical treatment of rectal cancer. The application of this technique has resulted in a pooled pelvic recurrence rate of approximately 7%. Preoperative and postoperative radiation further decreases the local regional recurrence (LRR) rate in patients with rectal cancer but the reduction in risk is counterbalanced by increased short and long term toxicity. Lower LRR rates have not uniformly translated into more favorable overall survival. In addition, advances in imaging have resulted in more accurate pretreatment staging and have improved the ability to stratify patients based on risk of recurrence. Given low pelvic recurrence rates after TME-based surgery alone, the risks and toxicities of pelvic radiation, and superior imaging to select high risk patients, radiation may not be requisite in the treatment of all rectal cancer patients. In this review, we discuss the current status of radiation and LRR rates in rectal cancer after definitive surgical resection with respect to specific subsites and stages of disease, examine the impact of imaging in the selection of patients for radiation, and raise the possibility that predictive biomarkers may help to identify patients who may not require pelvic radiation.
Keywords: Rectal cancer, chemoradiation, total mesorectal excision, local recurrence rates
Current Cancer Therapy Reviews
Title: The Changing Role of Radiation in the Post-TME ERA of Rectal Cancer
Volume: 6 Issue: 3
Author(s): Lily L. Lai and Charles R. Thomas Jr.
Affiliation:
Keywords: Rectal cancer, chemoradiation, total mesorectal excision, local recurrence rates
Abstract: Total mesorectal excision (TME) for rectal cancer is now considered standard in the surgical treatment of rectal cancer. The application of this technique has resulted in a pooled pelvic recurrence rate of approximately 7%. Preoperative and postoperative radiation further decreases the local regional recurrence (LRR) rate in patients with rectal cancer but the reduction in risk is counterbalanced by increased short and long term toxicity. Lower LRR rates have not uniformly translated into more favorable overall survival. In addition, advances in imaging have resulted in more accurate pretreatment staging and have improved the ability to stratify patients based on risk of recurrence. Given low pelvic recurrence rates after TME-based surgery alone, the risks and toxicities of pelvic radiation, and superior imaging to select high risk patients, radiation may not be requisite in the treatment of all rectal cancer patients. In this review, we discuss the current status of radiation and LRR rates in rectal cancer after definitive surgical resection with respect to specific subsites and stages of disease, examine the impact of imaging in the selection of patients for radiation, and raise the possibility that predictive biomarkers may help to identify patients who may not require pelvic radiation.
Export Options
About this article
Cite this article as:
L. Lai Lily and R. Thomas Jr. Charles, The Changing Role of Radiation in the Post-TME ERA of Rectal Cancer, Current Cancer Therapy Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339410791698179
DOI https://dx.doi.org/10.2174/157339410791698179 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microalgal Fatty Acids and Their Implication in Health and Disease
Mini-Reviews in Medicinal Chemistry Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening VEGF Inhibitors and Prostate Cancer Therapy
Current Molecular Pharmacology Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights
Current Neuropharmacology Vitamin D Deficiency: Universal Risk Factor for Multifactorial Diseases?
Current Drug Targets Regulation and Function of DNA and Histone Methylations
Current Pharmaceutical Design Berberine Interfered with Breast Cancer Cells Metabolism, Balancing Energy Homeostasis
Anti-Cancer Agents in Medicinal Chemistry Irinotecan or Oxaliplatin: Which is the First Move for the Mate?
Current Medicinal Chemistry Lycopene: A Review of Its Potential as an Anticancer Agent
Current Medicinal Chemistry - Anti-Cancer Agents Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer
Current Signal Transduction Therapy The Endocannabinoid System in the Cancer Therapy: An Overview
Current Medicinal Chemistry Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1
Current Drug Metabolism Mechanism of Action and Therapeutic Potential of Novel Adamantyl Retinoid-Related Molecules
Current Cancer Therapy Reviews Immediate Early Proto-Oncoproteins and Membranes: Not Just An Innocent Liaison
Current Protein & Peptide Science Anticancer Potential of Pulicaria crispa Extract on Human Breast Cancer MDA-MB-231 Cells
Letters in Drug Design & Discovery The SCF-type E3 Ubiquitin Ligases as Cancer Targets
Current Cancer Drug Targets Colon Cancer and Specific Ways to Deliver Drugs to the Large Intestine
Anti-Cancer Agents in Medicinal Chemistry Infringement of the Barriers of Cancer Via Dietary Phytoconstituents Capsaicin Through Novel Drug Delivery System
Current Drug Delivery Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design Vitamin D and Cancer Stem Cells in the Gastrointestinal Tract
Current Medicinal Chemistry